Ramatroban (INN) (also known as BAY u3405) is a thromboxane receptor antagonist. It is also a DP2 receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
ChemSpiderID |
|
F |
|
H |
|
IUPAC name |
|
KEGG |
|
legal status |
|
n |
|
O |
|
PubChem |
|
routes of administration |
|
s |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
tradename |
|
UNII |
|
has abstract |
|
IUPHAR ligand |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
CAS number |
|
ChEMBL |
|
FDA UNII code |
|
KEGG |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of |